Topics

Novus Therapeutics Receives FDA Guidance for Phase 2a POP201 Study

12:58 EDT 29 Oct 2019 | Investing News Network

The FDA has agreed with the company's proposed patient population, endpoints and plan for its Phase 2a study of OP0201.

The post Novus Therapeutics Receives FDA Guidance for Phase 2a POP201 Study appeared first on Investing News Network.

Original Article: Novus Therapeutics Receives FDA Guidance for Phase 2a POP201 Study

NEXT ARTICLE

More From BioPortfolio on "Novus Therapeutics Receives FDA Guidance for Phase 2a POP201 Study"

Quick Search